Clinical trials: Hepatocellular Carcinoma Recurrent
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases
- Trial name
- NCT01009593
- Testing
- ABT-869, Sorafenib
- Where
- 163 sites in United States, Argentina and 27 more
- Volunteers
- 1,035 people
- Sponsor
- Abbott
Hepatocellular Carcinoma, Recurrence
Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery
Evaluation the Treatment Outcome of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery.
- Trial name
- NCT01936233
- Testing
- Aspirin, Lamivudine
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC)
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
This study aims to compare the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma combined with high - risk recurrent factors.
- Trial name
- NCT06851104
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Resectable Hepatocellular Carcinoma
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ASPIRE (NCT07018947)
- Testing
- Atezolizumab and Bevacizumab
- Where
- 12 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery.
- Conditions
- Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Trial name
- NCT00553332
- Testing
- selumetinib, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Liver Metastases
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or cancer that has spread to the liver…
- Conditions
- Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02119065
- Testing
- positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Cincinnati
Solid Tumors, Soft Tissue Sarcoma
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
This is a pilot study of LTLD with MR-HIFU hyperthermia followed by ablation in subjects with refractory/relapsed solid tumors.
- Conditions
- Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm
- Trial name
- NCT04791228
- Testing
- Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
- Where
- United States
- Sponsor
- Children's National Research Institute
HCC
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06420440
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Chen Xiaoping